Results 51 to 60 of about 28,403 (261)

Linking Brain Morphometry to Psychometric Measures and Energy‐Metabolic Biomarkers in Adults With Autism Spectrum Disorder

Autism Research, EarlyView.
ABSTRACT Autism spectrum disorder (ASD) is associated with differences in neurodevelopment and altered metabolism, yet the interplay between brain morphometry, mitochondrial and energy metabolism biomarkers, and autistic traits in adults remains poorly understood. This study investigates the link between brain structure, psychometric measures, and both
Eleonora Esposto, Kathrin Nickel, Dominique Endres, Kimon Runge, Katharina Domschke, Thomas Lange, Marco Reisert, Anke Schumann, Cinzia Niolu, Ludger Tebartz van Elst, Simon Maier   +10 more
wiley   +1 more source

The Unique Roles of Executive Function in Co‐Occurring Psychopathologies in Autism

Autism Research, EarlyView.
ABSTRACT Children with autism spectrum disorder (ASD) often experience co‐occurring psychiatric conditions, such as anxiety and attention‐deficit/hyperactivity disorder (ADHD), which significantly impair daily functioning. However, the underlying mechanisms linking these conditions to core ASD features remain poorly understood.
Shing‐Him Ng, Jet Leung, Keith Chun Lok Lee, Angela Man Wai Lam, Isaac Ho Wai Wong, Sze‐Mai Ng, Maciej Gabrysiak, Petrina Yau Pok Lau, Sandra Sau Man Chan, Tyler M. Moore, Kosha Ruparel, Raquel E. Gur, Ruben C. Gur, Oscar Wing Ho Wong   +13 more
wiley   +1 more source

Effect of Atypical Antipsychotics on Fetal Growth: Is the Placenta Involved?

Journal of Pregnancy, 2012
There is currently considerable uncertainty regarding prescribing practices for pregnant women with severe and persistent psychiatric disorders. The physician and the mother have to balance the risks of untreated psychiatric illness against the potential
Sandeep Raha, Valerie H. Taylor, Alison C. Holloway   +2 more
doaj   +1 more source

Psychotropic medication use among community dwellers with and without Parkinson's disease – A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims We studied the prevalence of psychotropic use and psychotropic polypharmacy in persons with Parkinson's disease (PD) during a 10‐year follow‐up, because longitudinal studies on this topic are scarce although non‐motor symptoms of PD are often treated with psychotropics.
Noora Nieminen, Anna‐Maija Tolppanen, Valtteri Kaasinen, Marjaana Koponen, Sirpa Hartikainen   +4 more
wiley   +1 more source

ACKR1/Duffy‐null genotype testing for clozapine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, EarlyView.
Abstract Clozapine is licenced for treatment‐resistant schizophrenia and psychosis in Parkinson's disease. In the United Kingdom, there is a mandatory requirement for absolute neutrophil count (ANC) and white blood cell count (WBC) monitoring to safeguard against agranulocytosis.
Stephen Murtough, Oriella Stellakis, Daisy Mills, Blanca Bjourson, Vicky Chaplin, Dharmisha Chauhan, Bev Chipp, Marius Cotic, Jana de Villiers, Olubanké Dzahini, Frances Elmslie, Katie Evans, Shreyans Gandhi, Dyfrig A. Hughes, Huajie Jin, Daniele Panconesi, Anna Skowronska, Sanjay M. Sisodiya, Ed Silva, Vicky Stinton, Sara Stuart‐Smith, Sarah Tarrant, David Taylor, Lauren Varney, James T. R. Walters, Michelle Wood, Jessica Woodley, Cinzia Dello Russo, Munir Pirmohamed, Elvira Bramon   +29 more
wiley   +1 more source

A prospective series of acute rivaroxaban overdose, coagulopathy and bleeding complications (ATOM 11)

British Journal of Clinical Pharmacology, EarlyView.
Aim There is limited research describing rivaroxaban overdose. We aim to describe rivaroxaban overdose, coagulopathy and bleeding complications. Methods This is a prospective series of acute adult (>14 years) rivaroxaban overdose presentations >40 mg enrolled in the Australian Toxicology Monitoring study and presenting to three Australian clinical ...
Katherine Z. Isoardi, Angela L. Chiew, Keith Harris, Geoffrey K. Isbister   +3 more
wiley   +1 more source

CYP2C19 Genotype is Associated with Citalopram Treatment Outcomes in a Real‐World Setting

Clinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 metabolizes various selective serotonin reuptake inhibitors (SSRIs) and genetic CYP2C19 variants are associated with SSRI tolerability and response. Yet, whether CYP2C19 variability also impacts citalopram response remained unclear. We here evaluated associations between CYP2C19 genotypes and citalopram prescription data of 11,079 patients from
Yoomi Park, Yitian Zhou, Volker M. Lauschke   +2 more
wiley   +1 more source

Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the ÆSOP Study

, 2005
Typical antipsychotic drugs act on the dopaminergic system, blocking the dopamine type 2 (D2) receptors. Atypical antipsychotics have lower affinity and occupancy for the dopaminergic receptors, and a high degree of occupancy of the serotoninergic ...
Rosemarie M Mallett, Paola Dazzan, Hutchinson, G, Murray, R M, Ken Orr, Morgan, K.D., Mallett, R.M., Gerard Hutchinson, Jones, P.B., Xavier Chitnis, McGuire, P K, Philip K McGuire, Murray, R.M., Dazzan, P.; id_orcid, John Suckling, Chitnis, X, Kevin D Morgan, Robin M Murray, Leff, J., Suckling, J, Orr, K, Leff, J, Orr, K.G., Hutchinson, G., McGuire, P.K., Orr, K., Fearon, P, Paul Fearon, Jones, P B, Mallett, R M, Morgan, K D, Fearon, P., Suckling, J., Peter B Jones, Julian Leff, Dazzan, P; id_orcid, Dazzan, P., Chitnis, X.   +37 more
core   +1 more source

The influence of typical and atypical antipsychotics on neurocognitive functions in patients with psychotic disorders [PDF]

Hospital Pharmacology, 2019
Introduction: Although before, the prioritization of positive and negative symptoms of schizophrenia over neurocognitive impairment was of the highest importance, recent scientific achievements suggest that the disrupted neurocognitive functions are the ...
Javorac Jovan M., Janjić Gorana G., Živanović Dejan B., Javorac Tijana M., Marković Ana R.   +4 more
doaj  

The Serotonin 2B (5‐HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression

Clinical Pharmacology &Therapeutics, EarlyView.
Major depressive disorder (MDD) and treatment‐resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor‐level treatment strategies beyond monoamine reuptake. The serotonin 5‐HT2B receptor (5‐HT2BR) is uniquely positioned at the interface of central‐antidepressant mechanisms and peripheral cardiac risks.
Gia Han Le, Sabrina Wong, Danica E. Johnson, Diana K. Orsini, Yang Jing Zheng, Kayla M. Teopiz, Christine E. Dri, Joshua D. Rosenblat, Roger S. McIntyre   +8 more
wiley   +1 more source